Moffitt research suggests that sugar found in seaweed triggers potent antitumor immune responses and enhances immunotherapies

California voters pass $8.4B bond for immunotherapy research

In this year’s midterm election, voters in California approved Proposition 38, a $8.4 billion bond to fund immunology and immunotherapy research.

November 13, 2026

By Sara Willa Ernst

Clinical Roundup

Piktor regimen yields 33% confirmed ORR in advanced endometrial cancer, phase II study finds

Piktor, an investigational all-oral combination of serabelisib and sapanisertib, given with paclitaxel to patients with advanced endometrioid endometrial cancer and a PI3K/AKT/mTOR pathway mutation who had received at least one prior line of therapy, yielded a 33% confirmed objective response rate in efficacy-evaluable patients, and a disease control rate of 83%, according to clinical data from phase II trial (FTH-PIK-201; NCT06463028; GOG-311).

November 13, 2026

In Brief

Moffitt advances patient avatar technologies through $15M federal research initiative

Moffitt Cancer Center is advancing patient avatar technologies through a $15 million federally funded research initiative in collaboration with the Murtha Cancer Center Research Program at the Uniformed Services University of the Health Sciences in Bethesda, Maryland.

October 16, 2026

Vol.52 No.38

Clinical Roundup

UCLA scientists identify clues to making immunotherapy more effective against glioblastoma

Two studies led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center provide insight into how the immune system can successfully be activated against glioblastoma while revealing why these therapies have historically fallen short.

October 16, 2026

Vol.52 No.38

Clinical Roundup

Wistar Institute study identifies immunotherapy strategy for glioblastoma

Scientists at the Wistar Institute have identified a combination treatment that overcomes two of the biggest barriers to immunotherapy in glioblastoma. The researchers showed that reprogramming myeloid cells, a type of immune cell that glioblastoma tumors co-opt to protect themselves, while simultaneously boosting cancer-fighting T cells shrank the tumors and prevented them from coming back.

October 16, 2026

Vol.52 No.38

Clinical Roundup

UT Austin study uncovers new driver of immunotherapy resistance in pancreatic cancer

Pancreatic tumors can resist immunotherapy by recruiting nearby immune cells to help protect them, according to researchers at The University of Texas at Austin. The findings, published in Nature Communications, also point to a potential new strategy for overcoming resistance and improving cellular therapies.

September 18, 2026

Vol.52 No.34

Moffitt research suggests that sugar found in seaweed triggers potent antitumor immune responses and enhances immunotherapies

YOU MAY BE INTERESTED IN

California voters pass $8.4B bond for immunotherapy research

Piktor regimen yields 33% confirmed ORR in advanced endometrial cancer, phase II study finds

Moffitt advances patient avatar technologies through $15M federal research initiative

UCLA scientists identify clues to making immunotherapy more effective against glioblastoma

Wistar Institute study identifies immunotherapy strategy for glioblastoma

UT Austin study uncovers new driver of immunotherapy resistance in pancreatic cancer

Renew today!

Subscriber content

Never miss an issue!

Login